Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.

Leuratti C, Sardina M, Ventura P, Assandri A, Müller M, Brunner M.

Pharmacology. 2013;92(3-4):207-16. doi: 10.1159/000354805. Epub 2013 Oct 11.

PMID:
24136086
2.

Systemic absorption of rifamycin SV MMX administered as modified-release tablets in healthy volunteers.

Di Stefano AF, Rusca A, Loprete L, Dröge MJ, Moro L, Assandri A.

Antimicrob Agents Chemother. 2011 May;55(5):2122-8. doi: 10.1128/AAC.01504-10. Epub 2011 Mar 14.

3.

Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).

Saletu B, Anderer P, Wolzt M, Nosiska D, Assandri A, Noseda E, Nannipieri F, Saletu-Zyhlarz GM.

Neuropsychobiology. 2009;59(2):110-22. doi: 10.1159/000212380. Epub 2009 Apr 10.

PMID:
19365151
4.

Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.

Saletu-Zyhlarz GM, Anderer P, Wolzt M, Semlitsch HV, Assandri A, Nessi P, Nannipieri F, Rosini S, Saletu B.

Neuropsychobiology. 2009;59(2):100-9. doi: 10.1159/000212379. Epub 2009 Apr 10.

PMID:
19365150
5.

The immunosuppressor st1959, a 3,5-diaryl-s-triazole derivative, inhibits T cell activation by reducing NFAT nuclear residency.

Lindstedt R, Ruggiero V, D' Alessio V, Manganello S, Petronzelli F, Stasi MA, Vendetti S, Assandri A, Carminati P, De Santis R.

Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):29-42.

PMID:
19309550
6.

Double-blind, placebo-controlled, multiple-ascending-dose study on the effects of ABIO-08/01, a novel anxiolytic drug, on perception and cognition, utilizing event-related potential mapping and low-resolution brain electromagnetic tomography.

Anderer P, Saletu B, Wolzt M, Culic S, Assandri A, Nannipieri F, Rosini S, Saletu-Zyhlarz GM.

Hum Psychopharmacol. 2008 Apr;23(3):243-54. doi: 10.1002/hup.920.

PMID:
18181252
7.

Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry.

Arnold O, Saletu B, Anderer P, Assandri A, di Padova C, Corrado M, Saletu-Zyhlarz GM.

Eur Neuropsychopharmacol. 2005 Oct;15(5):533-43.

PMID:
16046102
8.

Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis.

Horak F, Stübner P, Zieglmayer R, Kavina A, Corrado ME, Assandri A, Mion A.

Arzneimittelforschung. 2004;54(10):666-72.

PMID:
15553106
9.

Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus terfenadine in the treatment of seasonal allergic rhinitis.

Corrado ME, Radicioni MM, Hartwig J, Assandri A, Oldeman HG, Mion A.

Arzneimittelforschung. 2004;54(10):660-5.

PMID:
15553105
10.

Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine (SAMe) infusions in elderly subjects, utilizing EEG mapping and psychometry.

Saletu B, Anderer P, Linzmayer L, Semlitsch HV, Lindeck-Pozza E, Assandri A, di Padova C, Saletu-Zyhlarz GM.

J Neural Transm (Vienna). 2002 Dec;109(12):1505-26.

PMID:
12486491
12.

Pharmacokinetic and mass balance study of unlabelled and (14)C-labelled emedastine difumarate in healthy volunteers.

Brunner M, Kletter K, Assandri A, Ermanno Corrado M, Eichler HG, Müller M.

Xenobiotica. 2002 Sep;32(9):761-70.

PMID:
12396273
13.

Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mapping.

Saletu-Zyhlarz GM, Anderer P, Linzmayer L, Semlitsch HV, Assandri A, Prause W, Hassan Abu-Bakr M, Lindeck-Pozza E, Saletu B.

Int J Neuropsychopharmacol. 2002 Sep;5(3):199-215. doi: 10.1017/S1461145702002924.

PMID:
12366873
14.

Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers.

Herranz U, Rusca A, Assandri A.

Int J Clin Pharmacol Ther. 2001 Mar;39(3):102-9.

PMID:
11396749
15.

Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment.

Joukhadar C, Herranz U, Pernerstorfer T, Assandri A, Klein N, Schrolnberger C, Lackner E, Eichler HG, Müller M.

Eur J Clin Pharmacol. 2001 Mar;56(12):905-10.

PMID:
11317479
16.

Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers.

Jansen B, Graselli U, Dallinger S, Kiss B, Wacheck V, Schlagbauer-Wadl H, Assandri A, Müller M.

Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):837-41.

PMID:
10805062
17.
18.

Pharmacokinetics and metabolism of N-(2-hydroxyethyl)-2,5-[14C]-pyrrolidine (HEP, Epolamine) in male healthy volunteers.

Giachetti C, Assandri A, Mautone G, Tajana E, Palumbo B, Palumbo R.

Eur J Drug Metab Pharmacokinet. 1996 Jul-Sep;21(3):261-8.

PMID:
8980926
19.

Gas chromatography-mass spectrometry determination of etodolac in human plasma following single epicutaneous administration.

Giachetti C, Assandri A, Zanolo G, Brembilla E.

Biomed Chromatogr. 1994 Jul-Aug;8(4):180-3.

PMID:
7812122
20.
21.
22.

Teicoplanin metabolism in rats.

Zerilli LF, Cavenaghi L, Bernareggi A, Assandri A.

Antimicrob Agents Chemother. 1989 Oct;33(10):1791-4.

23.

Determination of cyclic butylboronate esters of some 1,2- and 2,3-diols in plasma by high-resolution gas chromatography/mass spectrometry.

Giachetti C, Zanolo G, Assandri A, Poletti P.

Biomed Environ Mass Spectrom. 1989 Aug;18(8):592-7.

PMID:
2804444
24.

Metabolic oxidation of the pyrrole ring: structure and origin of some urinary metabolites of the anti-hypertensive pyrrolylpyridazinamine, mopidralazine. III: Studies with the 13C-labelled drug.

Assandri A, Tarzia G, Bellasio E, Ciabatti R, Tuan G, Ferrari P, Zerilli L, Lanfranchi M, Pelizzi G.

Xenobiotica. 1987 May;17(5):559-73.

PMID:
3604261
25.

Binding of teicoplanin to human serum albumin.

Assandri A, Bernareggi A.

Eur J Clin Pharmacol. 1987;33(2):191-5.

PMID:
2961570
26.

Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose.

Bernareggi A, Cavenaghi L, Assandri A.

Antimicrob Agents Chemother. 1986 Nov;30(5):733-8.

28.

Zetidoline metabolism by rat liver microsomes. Formation of metabolites with potential neuroleptic activity.

Assandri A, Galliani G, Zerilli L, Tuan G, Tarzia G, Barone D.

Biochem Pharmacol. 1986 May 1;35(9):1459-67.

PMID:
2871840
29.

Disposition of premazepam, an anti-anxiety pyrrolodiazepine, in the cynomolgus monkey.

Zanolo G, Giachetti MC, Canali S, Bernareggi A, Tarzia G, Assandri A.

Eur J Drug Metab Pharmacokinet. 1986 Apr-Jun;11(2):151-7.

PMID:
3770016
30.

On the mode of action of a new contragestational agent (DL 111-IT).

Galliani G, Luzzani F, Colombo G, Conz A, Mistrello L, Barone D, Lancini GC, Assandri A.

Contraception. 1986 Mar;33(3):263-83.

PMID:
2424668
31.

Metabolic pathways of the anti-hypertensive agent, N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride. II: Studies in the dog.

Assandri A, Perazzi A, Bellasio E, Ciabatti R, Tarzia G, Ferrari P, Ripamonti A, Tuan G, Zerilli LF.

Xenobiotica. 1985 Dec;15(12):1089-102.

PMID:
4090528
32.

Metabolic pathways of the anti-hypertensive agent, N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine+ ++ hydrochloride. I. Studies in the rat.

Assandri A, Perazzi A, Baldoli E, Ferrari P, Ripamonti A, Bellasio E, Tuan G, Zerilli F, Tarzia G.

Xenobiotica. 1985 Dec;15(12):1069-87.

PMID:
4090527
33.

Immunological profile of DL111-IT, a new immunosuppressant agent.

Mistrello G, Galliani G, Assandri A, Filippeschi S, Bassi L.

Immunopharmacology. 1985 Dec;10(3):163-9.

PMID:
3833855
34.

In vivo stereospecific [3H]spiperone binding in rat brain: characteristics, regional distribution, kinetics and pharmacological properties.

Barone D, Luzzani F, Assandri A, Galliani G, Mennini T, Garattini S.

Eur J Pharmacol. 1985 Oct 8;116(1-2):63-74.

PMID:
4054217
35.

Pharmacokinetics and metabolism of tomoxiprole, a new analgesic antiinflammatory agent, in the rat.

Assandri A, Bernareggi A, Ripamonti A, Perazzi A, Toja E.

Eur J Drug Metab Pharmacokinet. 1985 Apr-Jun;10(2):161-70.

PMID:
4043144
36.

Characterization of [3H]zetidoline binding to rat striatal membranes.

Barone D, Assandri A, Galliani G, Glässer A, Tarzia G.

J Pharm Pharmacol. 1985 Mar;37(3):180-7.

PMID:
2858565
37.

Contragestational profile of the tumor-inhibiting agent, L-alanosine, in the rat and the hamster.

Galliani G, Assandri A, Barone D, Grandi M, Mistrello G, Lancini GC.

Cancer Chemother Pharmacol. 1985;14(1):74-8.

PMID:
3965163
38.

Pharmacokinetics of a new antihypertensive pyrrolyl pyridazinamine (MDL-899) in the rat and the dog.

Assandri A, Bellasio E, Bernareggi A, Cristina T, Perazzi A, Odasso G.

Arzneimittelforschung. 1985;35(2):508-13.

PMID:
3855234
39.

Metabolic fate of zetidoline, a new neuroleptic agent, in man.

Assandri A, Perazzi A, Ferrari P, Martinelli E, Ripamonti A, Tarzia G, Tuan G.

Naunyn Schmiedebergs Arch Pharmacol. 1985 Jan;328(3):341-7.

PMID:
2858825
40.

Pharmacokinetics of rifapentine, a new long lasting rifamycin, in the rat, the mouse and the rabbit.

Assandri A, Ratti B, Cristina T.

J Antibiot (Tokyo). 1984 Sep;37(9):1066-75.

41.

Metabolism of the neuroleptic agent zetidoline in the rat and the dog.

Assandri A, Perazzi A, Fontanella L, Ferrari P, Ripamonti A, Tarzia G, Tuan G, Martinelli E.

Drug Metab Dispos. 1984 Sep-Oct;12(5):635-40.

PMID:
6149917
42.

Effect of deflazacort, a glucocorticoid with bone-sparing properties, on mixed lymphocyte response and skin graft rejection.

Mistrello G, Mapelli E, Galliani G, Cristina T, Assandri A.

Transplantation. 1984 Aug;38(2):192-4. No abstract available.

PMID:
6235649
43.

Metabolic pathways of the contragestational agent, 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole (DL 111-IT), in the rat.

Assandri A, Perazzi A, Ferrari P, Omodei-Salé A, Ripamonti A, Tuan G, Galliani G, Zerilli LF.

Xenobiotica. 1984 Jun;14(6):429-43.

PMID:
6475103
44.

Pharmacokinetics and metabolism of premazepam, a new potential anxiolytic, in humans.

Vitiello B, Buniva G, Bernareggi A, Assandri A, Perazzi A, Fuccella LM, Palumbo R.

Int J Clin Pharmacol Ther Toxicol. 1984 May;22(5):273-7.

PMID:
6146571
45.

Pharmacokinetics of isoprazone, a new analgesic antipyretic agent, in the rat.

Assandri A, Bernareggi A, Morrone A, Odasso G.

Farmaco Prat. 1984 Apr;39(4):118-30. No abstract available.

PMID:
6610564
46.

Metabolic fate of premazepam, a new anti-anxiety drug, in the rat and the dog.

Assandri A, Barone D, Ferrari P, Perazzi A, Ripamonti A, Tuan G, Zerilli LF.

Drug Metab Dispos. 1984 Mar-Apr;12(2):257-63.

PMID:
6144494
47.

Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man.

Assandri A, Buniva G, Martinelli E, Perazzi A, Zerilli L.

Adv Exp Med Biol. 1984;171:9-23. Review. No abstract available.

PMID:
6372406
48.

Disposition and metabolism of a new steroidal anti-inflammatory agent, deflazacort, in cynomolgus monkeys.

Assandri A, Ferrari P, Perazzi A, Ripamonti A, Tuan G, Zerilli L.

Xenobiotica. 1983 Mar;13(3):185-96.

PMID:
6613164
49.

Pharmacokinetics-activity relationships of a new non-hormonal antifertility agent: 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1, 2,4-triazole, in the rat and the hamster.

Assandri A, Perazzi A, Omodei-Salé A, Sartori G, Galliani G.

Eur J Drug Metab Pharmacokinet. 1983;8(1):9-16.

PMID:
6861799
50.

DL 111, a new non-hormonal antifertility agent: contragestational and kinetic profile in baboons.

Galliani G, Assandri A, Lerner LJ, Omodei-Salè A, Lancini G, Nock PE, Grant AM.

Contraception. 1982 Aug;26(2):165-79.

PMID:
7140293

Supplemental Content

Loading ...
Support Center